Cisplatin-based chemotherapy in recurrent or high risk ovarian granulosa-cell tumor patients
Chiara, S.; Merlini, L.; Campora, E.; Bruzzone, M.; Giudici, S.; Rosso, R.; Ragni, N.
European Journal of Gynaecological Oncology 14(4): 314-317
1993
ISSN/ISBN: 0392-2936 PMID: 8344327 Document Number: 417677
Nine chemotherapy-naive women with recurrent (2 patients) or high risk factors (bilateral or extraovarian spread, poorly-differentiated tumor, age > or = 40 years at diagnosis, residual disease after surgery) granulosa-cell tumors were treated with cisplatin, cyclophosphamide with or without doxorubicin (PAC, PC) or cisplatin, etoposide and bleamycin (PVP-16B). Toxicity was acceptable and the most frequently encountered adverse reactions were WHO grade 3 gastrointestinal toxicity in 77% of patients, and grade 3 myelosuppression in 22% of cases. Clinical complete response was achieved in the 2 patients with recurrent disease. Five patients underwent second look surgery which documented: complete response in 3 patients, partial response in 1 patient and progressive disease in 1 case. Median survival was 85 months (range 14-103). Cisplatin-based cytotoxic regimens may be of benefit in the treatment of recurrent or high risk granulosa-cell tumors.